Deerfield Invests $65 Million in Precision Immunology Startup

Boulevard Bio has launched with $65 million in funding from Deerfield Management, focusing on the development of its pipeline for autoimmune diseases. The company's co-founders include Professor Georg Schett, a researcher in the field of autoimmunity, and Frank Nestle, former Chief Scientific Officer of Sanofi. The funds will be used to advance the clinical development of BLVD-101, a candidate for IgA nephropathy (IgAN), and to support subsequent immunology programs. Despite being an early-stage company, the significant capital injection is driven by the clinical validation of BAFF/APRIL targets and the potential for improved convenience with chronic administration.

BLVD-101 Simultaneously Blocks BAFF and APRIL

BLVD-101 is a bispecific antibody in development, prior to brand and generic name assignment, designed to target both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), thereby inhibiting the production of pathogenic IgA and autoantibodies. It has entered Phase 1 clinical trials to evaluate safety, tolerability, and pharmacokinetics in healthy adults, with efficacy in patients to be demonstrated in subsequent trials. The company's stated target dosing interval is once every 12 weeks, which is longer than the weekly administration of Trutakna and the every-four-weeks administration of Voyxact. Therefore, the key to investment decisions lies in whether the initial pharmacokinetics support this interval and whether it leads to a reduction in proteinuria in IgAN patients.

Already Approved BAFF/APRIL Drugs Pose Entry Barriers

Vera Therapeutics' (VERA) Trutakna (atacicept-vymj), a TACI fusion protein that blocks BAFF/APRIL, received FDA accelerated approval on July 7, 2026, and is administered subcutaneously once weekly at a dose of 150 mg. Otsuka Holdings' (4578) Voyxact (sibeprenlimab-szsi), an APRIL-targeting antibody, received FDA accelerated approval on November 25, 2025, and is administered every four weeks at a dose of 400 mg. Existing standard treatments include RAS inhibitors and SGLT2 inhibitors, as well as Tarpeyo (budesonide), Filspari (sparsentan), Fabhalta (iptacopan), and Vanrafia (atrasentan). The IgAN therapeutics market is projected to grow from $2.8 billion in 2024 to $5.2 billion in 2034, presenting a significant opportunity. However, BLVD-101 must demonstrate clear differentiation in terms of efficacy, safety, and dosing convenience.

The Introduction of BLVD-201 Expands the Portfolio to Include B-Cell Depletion Strategies

Boulevard Bio has secured global development, manufacturing, and commercialization rights for MTS-128 from METiS TechBio (7666.HK) and is developing it as BLVD-201. BLVD-201 is a preclinical-stage trispecific T-cell engager (TCE) that links CD3 and CD19/BCMA on B cells, providing a simultaneous B-cell and antibody-secreting cell depletion approach. The agreement includes an upfront payment of $20 million, up to $1.6 billion in development, regulatory, and commercial milestones, and tiered sales royalties, for a total potential value of $1.62 billion. The advantage of using off-the-shelf antibodies simplifies manufacturing and supply compared to autologous CAR-T therapy, but clinical trial design to manage cytokine release syndrome and the risk of infection is critical to the platform's value.